Institute of Rheumatology, Belgrade, Serbia Report issue

Academic/Hospital Phase 1 Phase 3

Organization Overview

First Clinical Trial
2008
NCT00787137
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

University School of Medicine, Dir. Inst. of Rheumatology, Belgrade

Active Ingredients

Drugs in Phase 3 Trials (1)

adalimumab (humira) (1 trial)

Drugs in Phase 1 Trials (1)

pg-102 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Psoriatic (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2